RXRX
NASDAQ HealthcareRecursion Pharmaceuticals, Inc. - Class A Common Stock
Biotechnology
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
�� 市场数据
| 价格 | $3.78 |
|---|---|
| 成交量 | 14,129,744 |
| 市值 | 2.00B |
| 贝塔系数 | 1.010 |
| RSI（14日） | 76.6 超买 |
| 200日均线 | $4.62 |
| 50日均线 | $3.45 |
| 52周最高 | $7.18 |
| 52周最低 | $2.80 |
| Forward P/E | -4.44 |
| Price / Book | 1.77 |
🎯 投资策略评分
RXRX 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (76/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 💰 Dividend Daddy (26/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 RXRX in your text
粘贴任何文章、记录或帖子 — 工具将提取 RXRX 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.